Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Powered and controlled T-cell production.

Milone MC, Levine BL.

Nat Biomed Eng. 2018 Mar;2(3):148-150. doi: 10.1038/s41551-018-0206-1. No abstract available.

PMID:
31015722
2.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.

J Clin Invest. 2019 Mar 21;130:2210-2221. doi: 10.1172/JCI126397.

3.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

4.

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA.

Am J Hematol. 2019 May;94(S1):S3-S9. doi: 10.1002/ajh.25418. Epub 2019 Feb 18. Review.

PMID:
30680780
5.

Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.

Thibodeaux SR, Milone MC.

Clin Chem. 2019 Apr;65(4):519-529. doi: 10.1373/clinchem.2016.258988. Epub 2018 Dec 28. Review.

PMID:
30593467
6.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

PMID:
30030295
7.

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.

Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC.

Oncotarget. 2018 May 25;9(40):25764-25780. doi: 10.18632/oncotarget.25359. eCollection 2018 May 25.

8.

The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.

O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC.

Sci Rep. 2018 Apr 19;8(1):6289. doi: 10.1038/s41598-018-24676-6.

9.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

10.

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.

Laetsch TW, Maude SL, Milone MC, Davis KL, Krueger J, Cardenas AM, Eldjerou LK, Keir CH, Wood PA, Grupp SA.

Blood. 2018 Jun 7;131(23):2596-2598. doi: 10.1182/blood-2017-12-822940. Epub 2018 Apr 18. No abstract available.

11.

Clinical use of lentiviral vectors.

Milone MC, O'Doherty U.

Leukemia. 2018 Jul;32(7):1529-1541. doi: 10.1038/s41375-018-0106-0. Epub 2018 Mar 22. Review.

12.

Neurotoxicity Associated with a High-Affinity GD2 CAR-Response.

Richman SA, Milone MC.

Cancer Immunol Res. 2018 Apr;6(4):496-497. doi: 10.1158/2326-6066.CIR-18-0090. No abstract available.

13.

CAR T cell immunotherapy for human cancer.

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC.

Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711. Review.

PMID:
29567707
14.

The Pharmacology of T Cell Therapies.

Milone MC, Bhoj VG.

Mol Ther Methods Clin Dev. 2018 Jan 31;8:210-221. doi: 10.1016/j.omtm.2018.01.010. eCollection 2018 Mar 16. Review.

15.

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.

Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA, Milone MC.

Cancer Immunol Res. 2018 Jan;6(1):36-46. doi: 10.1158/2326-6066.CIR-17-0211. Epub 2017 Nov 27.

16.

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.

Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD.

Am J Kidney Dis. 2018 Mar;71(3):315-326. doi: 10.1053/j.ajkd.2017.07.018. Epub 2017 Nov 20.

17.

Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA.

Kawalekar O, June CH, Milone MC.

Methods Mol Biol. 2017;1584:443-450. doi: 10.1007/978-1-4939-6881-7_27.

PMID:
28255718
18.

Improving T Cell Expansion with a Soft Touch.

Lambert LH, Goebrecht GK, De Leo SE, O'Connor RS, Nunez-Cruz S, Li TD, Yuan J, Milone MC, Kam LC.

Nano Lett. 2017 Feb 8;17(2):821-826. doi: 10.1021/acs.nanolett.6b04071. Epub 2017 Jan 30.

19.

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease.

Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS.

Science. 2016 Jul 8;353(6295):179-84. doi: 10.1126/science.aaf6756. Epub 2016 Jun 30.

20.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR.

J Clin Invest. 2016 Jul 1;126(7):2642-60. doi: 10.1172/JCI85796. Epub 2016 Jun 13.

21.

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, Feldman MD, Porter DL, Grupp SA, June CH, Milone MC.

Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May 10.

22.

High-Throughput Mechanobiology Screening Platform Using Micro- and Nanotopography.

Hu J, Gondarenko AA, Dang AP, Bashour KT, O'Connor RS, Lee S, Liapis A, Ghassemi S, Milone MC, Sheetz MP, Dustin ML, Kam LC, Hone JC.

Nano Lett. 2016 Apr 13;16(4):2198-204. doi: 10.1021/acs.nanolett.5b04364. Epub 2016 Mar 23.

23.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Mar 15;44(3):712. doi: 10.1016/j.immuni.2016.02.023. Epub 2016 Mar 15. No abstract available.

24.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Feb 16;44(2):380-90. doi: 10.1016/j.immuni.2016.01.021. Erratum in: Immunity. 2016 Mar 15;44(3):712. Snyder, Nathaniel [corrected to Snyder, Nathaniel W]; Blair, Ian [corrected to Blair, Ian A]. Immunity. 2016 Mar 15;44(3):712.

25.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH.

Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.

26.

Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.

Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Puré E, Albelda S, Milone MC.

Cancer Immunol Res. 2015 Jul;3(7):815-26. doi: 10.1158/2326-6066.CIR-15-0054. Epub 2015 May 4.

27.

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ, Hsieh AL, Gouw AM, Thomas AG, Gao P, Sun L, Song L, Yan B, Slusher BS, Zhuo J, Ooi LL, Lee CG, Mancuso A, McCallion AS, Le A, Milone MC, Rayport S, Felsher DW, Dang CV.

J Clin Invest. 2015 Jun;125(6):2293-306. doi: 10.1172/JCI75836. Epub 2015 Apr 27.

28.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

29.

Breaking the therapeutic drug monitoring logistics barrier.

Milone MC, Shaw LM.

Clin Chem. 2014 Dec;60(12):1471-2. doi: 10.1373/clinchem.2014.222935. Epub 2014 Jun 23. No abstract available.

30.

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.

Clin Cancer Res. 2014 Aug 15;20(16):4262-73. doi: 10.1158/1078-0432.CCR-13-2627. Epub 2014 Jun 11.

31.

Cross talk between CD3 and CD28 is spatially modulated by protein lateral mobility.

Bashour KT, Tsai J, Shen K, Lee JH, Sun E, Milone MC, Dustin ML, Kam LC.

Mol Cell Biol. 2014 Mar;34(6):955-64. doi: 10.1128/MCB.00842-13. Epub 2013 Dec 30.

32.

Eltrombopag and serum of a different hue.

Cardamone D, Milone MC, Glaser L, Frey NV, Kricka LJ.

Arch Pathol Lab Med. 2013 Sep;137(9):1175. doi: 10.5858/arpa.2012-0716-LE. No abstract available.

PMID:
23991726
33.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH.

N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.

34.

Commentary.

Milone MC.

Clin Chem. 2012 Dec;58(12):1635. doi: 10.1373/clinchem.2012.184127. No abstract available.

35.

Laboratory testing for prescription opioids.

Milone MC.

J Med Toxicol. 2012 Dec;8(4):408-16. doi: 10.1007/s13181-012-0274-7. Review.

36.

Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation.

Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, June CH.

Hum Gene Ther. 2013 Jan;24(1):27-37. doi: 10.1089/hum.2012.130. Epub 2012 Nov 6.

37.

Investigative and clinical applications of synthetic immune synapses.

Milone MC, Kam LC.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Jan-Feb;5(1):75-85. doi: 10.1002/wnan.1195. Epub 2012 Aug 23. Review.

38.

Substrate rigidity regulates human T cell activation and proliferation.

O'Connor RS, Hao X, Shen K, Bashour K, Akimova T, Hancock WW, Kam LC, Milone MC.

J Immunol. 2012 Aug 1;189(3):1330-9. doi: 10.4049/jimmunol.1102757. Epub 2012 Jun 25.

39.

The next GME accreditation system.

Milone MC.

N Engl J Med. 2012 Jun 14;366(24):2324-5; author reply 2325. doi: 10.1056/NEJMc1204398. No abstract available.

PMID:
22694013
40.

The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.

Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS.

Bone Marrow Transplant. 2013 Jan;48(1):19-25. doi: 10.1038/bmt.2012.105. Epub 2012 Jun 11.

PMID:
22684047
41.

F-actin polymerization and retrograde flow drive sustained PLCγ1 signaling during T cell activation.

Babich A, Li S, O'Connor RS, Milone MC, Freedman BD, Burkhardt JK.

J Cell Biol. 2012 Jun 11;197(6):775-87. doi: 10.1083/jcb.201201018. Epub 2012 Jun 4.

42.

Parental and late adolescent psychopathology: mothers may provide support when needed most.

McKinney C, Milone MC.

Child Psychiatry Hum Dev. 2012 Oct;43(5):747-60. doi: 10.1007/s10578-012-0293-2.

PMID:
22392416
43.

Hyponatremia associated with levamisole-adulterated cocaine use in emergency department patients.

Friend K, Milone MC, Perrone J.

Ann Emerg Med. 2012 Jul;60(1):94-6. doi: 10.1016/j.annemergmed.2011.08.022. Epub 2011 Sep 29.

PMID:
21958733
44.

Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.

Zhang Q, Wang H, Kantekure K, Paterson JC, Liu X, Schaffer A, Paulos C, Milone MC, Odum N, Turner S, Marafioti T, Wasik MA.

Blood. 2011 Sep 15;118(11):3062-71. doi: 10.1182/blood-2011-01-332916. Epub 2011 Jul 15.

45.

Commentary.

Milone MC.

Clin Chem. 2011 May;57(5):674. doi: 10.1373/clinchem.2010.159129. No abstract available.

46.

High-resolution imaging of the immunological synapse and T-cell receptor microclustering through microfabricated substrates.

Biggs MJ, Milone MC, Santos LC, Gondarenko A, Wind SJ.

J R Soc Interface. 2011 Oct 7;8(63):1462-71. doi: 10.1098/rsif.2011.0025. Epub 2011 Apr 13.

47.

Parenting and late adolescent emotional adjustment: mediating effects of discipline and gender.

McKinney C, Milone MC, Renk K.

Child Psychiatry Hum Dev. 2011 Aug;42(4):463-81. doi: 10.1007/s10578-011-0229-2.

PMID:
21479509
48.

Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.

Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C.

Bone Marrow Transplant. 2011 Nov;46(11):1418-25. doi: 10.1038/bmt.2010.315. Epub 2010 Dec 6.

PMID:
21132026
49.

Commentary.

Milone MC.

Clin Chem. 2010 Dec;56(12):1795-6. doi: 10.1373/clinchem.2010.153619. No abstract available.

50.

Increased risk of citrate reactions in patients with multiple myeloma during peripheral blood stem cell leukapheresis.

Adamski J, Griffin AC, Eisenmann C, Milone MC, Sachais BS.

J Clin Apher. 2010;25(4):188-94. doi: 10.1002/jca.20235.

PMID:
20818713

Supplemental Content

Loading ...
Support Center